Glovista Investments LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,700 shares of the medical equipment provider’s stock after selling 100 shares during the period. Glovista Investments LLC’s holdings in Zimmer Biomet Holdings were worth $732,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in ZBH. Parkside Financial Bank & Trust boosted its position in Zimmer Biomet Holdings by 2.7% during the 1st quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 22 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC boosted its position in Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 199 shares during the period. IHT Wealth Management LLC boosted its position in Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 256 shares during the period. Finally, Sandy Spring Bank boosted its position in Zimmer Biomet Holdings by 1.7% during the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after purchasing an additional 20 shares during the period. 85.35% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.07% of the stock is currently owned by insiders.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 1.24% during midday trading on Friday, reaching $117.09. 1,058,684 shares of the company traded hands. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49. The firm has a market capitalization of $23.68 billion, a price-to-earnings ratio of 33.35 and a beta of 1.21. The firm’s 50 day moving average price is $114.50 and its 200 day moving average price is $120.75.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($0.02). The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.02 earnings per share. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 27.59%.

A number of brokerages recently weighed in on ZBH. Zacks Investment Research raised shares of Zimmer Biomet Holdings from a “sell” rating to a “hold” rating in a research report on Tuesday. Gabelli began coverage on shares of Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price target for the company. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Monday, August 14th. BidaskClub cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets upped their price target on shares of Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $136.58.

COPYRIGHT VIOLATION NOTICE: “Glovista Investments LLC Decreases Position in Zimmer Biomet Holdings, Inc. (ZBH)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/30/glovista-investments-llc-decreases-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.